This article is more than 5 years old. Information may no longer be current.

Inotek initiates phase 2 trial for fixed-dose combination of trabodenoson, latanoprost

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Inotek Pharmaceuticals has initiated a phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost for the treatment of patients with ocular hypertension or primary open-angle glaucoma, the company announced in a press release.

The randomized, double-masked trial will include approximately 165 patients with an IOP between 25 mm Hg and 34 mm Hg. Patients will receive various topical combinations of trabodenoson and latanoprost or latanoprost alone over 8 weeks.

“Trabodenoson is designed to restore the eye’s natural pressure by increasing aqueous humor outflow via the trabecular meshwork, the primary outflow apparatus of the eye and a site of pathology in glaucoma,” Rudolf Baumgartner, MD, chief medical officer of Inotek, said in the release.

The company expects to announce data from the trial in 2017.